Release No 8/2010
Affitech Signs Strategic Alliance
with Russian Biotech Partner
NauchTekhStroy Plus, (NTS Plus), a newly formed joint venture subsidiary of
Pharmstandard, Russia's leading domestic pharmaceutical company and a
participant in the leading Russian biotech project ‘Generium', will conduct
clinical development and registration of two innovative Affitech antibodies for
Russian and CIS markets
- NTS Plus will pay €23 million in fees and advanced royalties to Affitech
- Pharmstandard will commercialise these antibody products in Russia and CIS
- Russian Investor, Trans Nova Investments, becomes majority shareholder in
Affitech by subscribing for €20.9 million in new Affitech shares
- Affitech shares continue to trade on NASDAQ/OMX Copenhagen Stock Exchange
--------------------------------------------------------------------------------
| For more information please contact: |
--------------------------------------------------------------------------------
| |
| Affitech A/S: |
| |
| Dr Robert Burns, Chief Executive Officer, |
| Tel # +45 5590 7642 |
| Randi Krogsgaard, Corporate Communications |
| Tel # +45 2320 1001 |
| Randi@affitech.com |
| NTS Plus/Pharmstandard: |
| Krylov Igor, Chief Executive Officer, |
| Tel # +7 495 970-00-34 |
| Arkhangelskaya Elena , Chief Financial Officer, |
| Tel # +7 495 970-00-35 |
--------------------------------------------------------------------------------
